2026 NPPES data Hematology & Oncology Physician NPI 1740383181 MD
Verify on CMS →

MARIE AMANZE, MD

Hematology & Oncology Physician in TALLAHASSEE, Florida. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
2K
Medicare Part D claims · 195 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
72%
generic claims · 28% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$6.11
1 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: MARIE AMANZE, MD is a Hematology & Oncology Physician ([object Object]) practicing in TALLAHASSEE, Florida with a Medicare Part D prescribing footprint of 2K claims across 195 beneficiaries — 28% brand-name prescribing . Industry payments of $6.11 across 1 transactions are disclosed under CMS Open Payments (Sunshine Act).

What stands out: MARIE AMANZE, MD filed 1,526 Medicare Part D claims in 2023 across TALLAHASSEE, Florida. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board-eligible specialty (heuristic — not verified)

MARIE AMANZE, MD practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).

MARIE AMANZE, MD at a glance

Quality data not reported

NPI registry status

Active

Issued 09/07/2006

NPI 1740383181

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

1,526 80% vs specialty avg

2023 prescription claims

Specialty avg: 847

Specialty distribution in Florida

How Hematology & Oncology Physician compares to other specialties among Florida providers

Florida providers

Hematology & Oncology Physician share within Florida

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within Florida

Specialty board-certification context

Estimated specialty board-certified rate — Hematology & Oncology Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Hematology & Oncology Physician ABMS/AOA estimate

Est. board-certified rate (Hematology & Oncology Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Hematology & Oncology Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MARIE AMANZE, MD is a Hematology & Oncology Physician provider practicing in TALLAHASSEE, Florida, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: MD. NPI: 1740383181. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

MARIE AMANZE, MD appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding MD credentials at 1309 THOMASWOOD DR, TALLAHASSEE, FL, 32308, with a listed phone of (850) 727-8540. NPI 1740383181 was issued on 09/07/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what AMANZE most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 1,526 prescription claims written by this provider, covering 195 Medicare beneficiaries and totaling roughly $4.1 million in drug spend, split 28% brand-name and 72% generic by claim count, with an opioid prescribing rate of 14.1%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1309 THOMASWOOD DR
TALLAHASSEE, FL 32308

Provider Details

NPI 1740383181
Specialty Hematology & Oncology Physician
Credentials MD
Gender Female
NPI Issued 09/07/2006

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MARIE AMANZE, MD. Source: openpaymentsdata.cms.gov.

Total received

$6

Largest payer

Rigel Pharmaceuticals, Inc.

Most common payment type

Education

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Florida FLDOH 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~75K Florida medical licensees in 2023 — they are NOT specific to MARIE AMANZE, MD. To verify MARIE AMANZE, MD's current license status, search the FLDOH public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

480
Total board actions, Florida 2023
Across 467 cases
6.40
Actions per 1,000 licensees
Florida statewide rate
monetary fine
Most common action type
138 cases

FLDOH publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Florida disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

MARIE AMANZE, MD — brand share 28.0%
Specialty average (est.)

28% brand-name claims vs 72% generic, on 1,526 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

1,526
Total Claims
$4.1M
Total Drug Cost
195
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
1,976
Total Day Supply
54,591
Brand vs Generic
28% brand / 72% generic
Brand Drug Cost
$3.7M
Generic Drug Cost
$345K
Opioid Claims
215 (14.1% rate)
Antibiotic Claims
46

Patient Demographics

Average Patient Age
70.0 years
Avg HCC Risk Score
2.21
Gender Split
75% female / 25% male
Age Distribution
<65: 39, 65-74: 88, 75-84: 54, 85+: 14

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Anastrozole
166
Eliquis
Apixaban
121
Oxycodone-Acetaminophen
Oxycodone Hcl/Acetaminophen
81
Pomalyst
Pomalidomide
66
Hydroxyurea
58
Ondansetron Hcl
56
Valacyclovir
Valacyclovir Hcl
49
Xarelto
Rivaroxaban
49
Oxycodone Hcl
44
Gabapentin
43

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How MARIE AMANZE, MD fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

MARIE AMANZE, MD's 1,526 claims are above the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in Florida

Other clinicians with the same primary specialty enrolled in Florida, drawn from the same CMS NPPES roster as AMANZE.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is MARIE AMANZE, MD's specialty?
MARIE AMANZE, MD specializes in Hematology & Oncology Physician and practices in TALLAHASSEE, Florida. Credentials: MD.
How much does MARIE AMANZE, MD prescribe under Medicare Part D?
In 2023, MARIE AMANZE, MD wrote 1,526 Medicare Part D claims totaling $4.1M in drug costs for 195 beneficiaries.
Where is MARIE AMANZE, MD located?
MARIE AMANZE, MD is located at 1309 THOMASWOOD DR, TALLAHASSEE, FL, 32308. Phone: (850) 727-8540.
What is MARIE AMANZE, MD's NPI number?
MARIE AMANZE, MD's National Provider Identifier (NPI) is 1740383181, issued on 09/07/2006.
Does MARIE AMANZE, MD prescribe more brand-name or generic drugs?
MARIE AMANZE, MD's prescribing is 28% brand-name and 72% generic drugs by claim count, with $3.7M in brand drug costs.
Does MARIE AMANZE, MD prescribe opioids?
Yes, MARIE AMANZE, MD had 215 opioid claims in 2023 with an opioid prescribing rate of 14.1%.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does MARIE AMANZE, MD prescribe most often?
Based on 2023 Medicare Part D data, MARIE AMANZE, MD's most frequently prescribed drugs include Anastrozole, Eliquis, Oxycodone-Acetaminophen. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MARIE AMANZE, MD accept Medicare?
MARIE AMANZE, MD appears in CMS Medicare data with 1,526 Part D claims and 195 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MARIE AMANZE, MD's credentials?
MARIE AMANZE, MD's NPI is 1740383181 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology